Participants with any of the following:\r\n* History of myocardial infarction within six months\r\n* Unstable angina\r\n* History of cerebrovascular accident (CVA) within 6 months\r\n* New York Heart Association grade II or greater congestive heart failure\r\n* Significant vascular disease (e.g. aortic aneurysm, history of aortic dissection)\r\n* Clinically significant peripheral vascular disease
Significant vascular disease (e.g., aortic aneurysm, aortic dissection, symptomatic peripheral vascular disease)
Clinically significant peripheral vascular disease or vascular disease (abdominal aortic aneurysm > 5 cm) or aortic dissection; if known history of abdominal aortic aneurysm with >= 4 cm in diameter, all of the following must be met\r\n* An ultrasound within the last 6 months required to document that it is =< 5 cm\r\n* Patient must be asymptomatic from the aneurysm\r\n* Blood pressure must be well controlled as defined in this protocol
Patients with symptomatic peripheral vascular disease are not eligible
Significant cardiovascular or cerebrovascular disease including:\r\n* Uncontrolled hypertension (systolic blood pressure [SBP] >= 150; diastolic blood pressure [DBP] >= 90)\r\n* History of myocardial infarction within 6 months\r\n* Unstable angina\r\n* New York Heart Association functional classification II, III or IV\r\n* Baseline ejection fraction =< 50% as assessed by echocardiogram or multi-gated acquisition (MUGA)\r\n* Cerebral vascular accident (CVA) or transient ischemic attack (TIA) within 6 months\r\n* Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or peripheral arterial thrombosis) within 6 months
Patients with history of active collagen vascular disease
Symptomatic peripheral vascular disease
Significant known vascular disease (e.g. aortic aneurysm, aortic dissection)
Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to day 1
No symptomatic peripheral arterial disease
Uncontrolled intercurrent illness including, but not limited to, severe or unstable angina, myocardial infarction, symptomatic congestive heart failure (defined as New York Heart Association grade II or greater), arterial or venous thromboembolic events (e.g., pulmonary embolism), or clinically significant ventricular arrhythmias, significant vascular disease (e.g. aortic aneurysm, aortic dissection), or symptomatic peripheral vascular disease within 6 months prior to registration
Significant vascular disease (e.g., aortic aneurysm, aortic dissection, symptomatic peripheral vascular disease including claudication, Leo Buerger's disease). Treated peripheral vascular disease that is stable for at least 6 months is allowed.
History of deep venous thrombosis, clinically significant peripheral vascular disease, or other thrombotic event
Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to day 1
Patients with clinically significant cardiovascular disease are excluded\r\n* Inadequately controlled hypertension (HTN) (systolic blood pressure [SBP] > 160 mmHg and/or diastolic blood pressure [DBP] > 90 mmHg despite antihypertensive medication)\r\n* History of cerebrovascular accident (CVA) within 6 months\r\n* Myocardial infarction or unstable angina within 6 months\r\n* Serious and inadequately controlled cardiac arrhythmia\r\n* Significant vascular disease (e.g. aortic aneurysm, history of aortic dissection)\r\n* Clinically significant peripheral vascular disease
Known active collagen vascular disease
Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to day 1
Clinically significant peripheral vascular disease or known abdominal aortic aneurysm ( > 5 cm in diameter) or history of aortic dissection; patients with known history of abdominal aortic aneurysm (AAA) with >= 4 cm in diameter, a repeat ultrasound (US) within the last 6 months prior to randomization will be required to document that it is =< 5 cm, and patient must be asymptomatic from the aneurysm, and the blood pressure must be well controlled as required in this protocol
Active collagen vascular disease
(Bevacizumab-related exclusion) Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior of study enrollment
Clinically-significant cardiac disease:\r\n* Recent myocardial infarction (=< 6 months prior to day 1)\r\n* Unstable angina pectoris\r\n* Uncontrolled congestive heart failure (New York Heart Association > class II)\r\n* Uncontrolled hypertension (>= Common Terminology Criteria for Adverse Events [CTCAE] version [v]4.03 grade 3)\r\n* Prior history of hypertensive crisis or hypertensive encephalopathy\r\n* Uncontrolled cardiac arrhythmias\r\n* Clinically-significant vascular disease (e.g. aortic aneurysm, or dissecting aneurysm)\r\n* Severe aortic stenosis\r\n* Clinically significant peripheral vascular disease\r\n* >= Grade 3 cardiac toxicity following prior chemotherapy\r\n* Corrected QT interval (QTc) > 470 for females and > 450 for males
Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis ? 6 months of study enrollment
Clinically significant peripheral vascular disease or abdominal aortic aneurysm (> 5 cm) or aortic dissection; if known history of abdominal aortic aneurysm with >= 4 cm in diameter, all of the following must be met: \r\n* An ultrasound (US) within the last 6 months prior to registration will be required to document that it is =< 5 cm\r\n* Patient must be asymptomatic from the aneurysm\r\n* Blood pressure must be well controlled as defined in this protocol
Significant vascular disease or recent peripheral arterial thrombosis
Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to enrollment;
systemic vascular disease or vasculitis
Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to cycle 1, day 1
Vascular invasion
PHASE II STUDY COHORT 1 OVARIAN CANCER ELIGIBILITY CRITERIA (MEDI+O, MEDI+C AND MEDI+O+C):\r\nPatients with any cardiac history of the following conditions within 1 year prior to MEDI+O arm or within 2 years prior to MEDI+C or MEDI+O+C arm enrollment are excluded from the study:\r\n• Prior events including myocardial infarction, clinically significant pericardial effusion, and myocarditis\r\n• Prior cardiac arrhythmia including atrial fibrillation (except chronic atrial fibrillation with controlled vascular rate), and atrial flutter, or requiring concurrent use of drugs or biologics with pro-arrhythmic potential\r\n• NYHA class II or greater heart failure\r\n• If cardiac function assessment is clinically indicated or performed, an LVEF less than normal per institutional guidelines, or < 55%, if threshold for normal is not otherwise specified by institutional guidelines\r\n• Mean QT interval corrected for heart rate (QTc) >= 470 ms calculated from 3 (ECGs) using Fridericia’s correction or other significant ECG abnormality noted within 14 days of treatment\r\n• Hypertensive crisis or hypertensive encephalopathy\r\n• Clinically significant peripheral vascular disease or vascular disease, including rapidly growing aortic aneurysm or abdominal aortic aneurysm > 5 cm or aortic dissection\r\n• Unstable angina
PHASE II STUDY COHORT 5 TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nPatients with any cardiac history of the following conditions within 1 year prior to study enrollment are excluded from the study:\r\n* Prior events including myocardial infarction, clinically significant pericardial effusion, and myocarditis\r\n* Prior cardiac arrhythmia including atrial fibrillation (except chronic atrial fibrillation with controlled vascular rate) and atrial flutter, or requiring concurrent use of drugs or biologics with pro-arrhythmic potential\r\n* NYHA class II or greater heart failure\r\n* If cardiac function assessment is clinically indicated or performed, an LVEF less than normal per institutional guidelines, or < 55%, if threshold for normal is not otherwise specified by institutional guidelines\r\n* Mean QT interval corrected for heart rate (QTc) >= 470 ms calculated from 3 electrocardiograms (ECGs) using Fridericia’s correction or other significant ECG abnormality noted within 14 days of treatment\r\n* Clinically significant peripheral vascular disease or vascular disease, including rapidly growing aortic aneurysm or abdominal aortic aneurysm > 5 cm or aortic dissection\r\n* Unstable angina
PHASE II STUDY NON-SMALL CELL LUNG CANCER (COHORT 2; MEDI+O AND MEDI+C) AND SMALL CELL LUNG CANCER (COHORT 3; MEDI+O ONLY) ELIGIBILITY CRITERIA:\r\nPatients with any cardiac history of the following conditions within 1 year prior to MEDI+O study or within 2 years prior to MEDI+C study enrollment are excluded from the study:\r\n* Prior events including myocardial infarction, clinically significant pericardial effusion, and myocarditis\r\n* Prior cardiac arrhythmia including atrial fibrillation (except chronic atrial fibrillation with controlled vascular rate) and atrial flutter, or requiring concurrent use of drugs or biologics with pro-arrhythmic potential\r\n* NYHA class II or greater heart failure\r\n* If cardiac function assessment is clinically indicated or performed, an LVEF less than normal per institutional guidelines, or < 55%, if threshold for normal is not otherwise specified by institutional guidelines\r\n* Mean QT interval corrected for heart rate (QTc) >= 470 ms calculated from 3 electrocardiograms (ECGs) using Fridericia’s correction or other significant ECG abnormality noted within 14 days of treatment\r\n* Hypertensive crisis or hypertensive encephalopathy\r\n* Clinically significant peripheral vascular disease or vascular disease, including rapidly growing aortic aneurysm or abdominal aortic aneurysm > 5 cm or aortic dissection\r\n* Unstable angina
PHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nPatients with any cardiac history of the following conditions within 2 years prior to study enrollment are excluded from the study:\r\n* Prior events including myocardial infarction, clinically significant pericardial effusion, and myocarditis\r\n* Prior cardiac arrhythmia including atrial fibrillation and atrial flutter, or requiring concurrent use of drugs or biologics with pro-arrhythmic potential\r\n* NYHA Class II or greater heart failure\r\n* If cardiac function assessment is clinically indicated or performed, an LVEF less than normal per institutional guidelines, or < 55%, if threshold for normal is not otherwise specified by institutional guidelines\r\n* Mean QT interval corrected for heart rate (QTc) >= 470 ms calculated from 3 electrocardiograms (ECGs) using Fridericia’s correction or other significant ECG abnormality noted within 14 days of treatment\r\n* Hypertensive crisis or hypertensive encephalopathy\r\n* Clinically significant peripheral vascular disease or vascular disease, including rapidly growing aortic aneurysm or abdominal aortic aneurysm > 5 cm or aortic dissection\r\n* Unstable angina
Subject has a grade II or greater peripheral vascular disease
Clinically significant peripheral vascular disease or vascular disease (including aortic aneurysm or aortic dissection)
Clinically significant peripheral vascular disease
Significant vascular disease (e.g., aortic aneurysm, aortic dissection)
Symptomatic peripheral vascular disease
Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to day 1
Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent peripheral arterial thrombosis within 6 months prior to day 1
Clinically significant peripheral vascular disease
Severe, active co-morbidity, defined as follows:\r\n* Unstable angina and/or congestive heart failure within the last 6 months\r\n* Transmural myocardial infarction within the last 6 months\r\n* New York Heart Association grade II or greater congestive heart failure requiring hospitalization within 12 months prior to registration\r\n* History of stroke, cerebral vascular accident (CVA) or transient ischemic attack within 6 months\r\n* Serious and inadequately controlled cardiac arrhythmia\r\n* Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection) or clinically significant peripheral vascular disease\r\n* Evidence of bleeding diathesis or coagulopathy\r\n* Serious or non-healing wound, ulcer, or bone fracture or history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess, major surgical procedure or significant traumatic injury within 28 days prior to registration, with the exception of the craniotomy for tumor resection or follow-on craniotomies to manage complications of brain tumor management such as hemorrhage or infection\r\n* Bacterial or fungal infection requiring intravenous antibiotics at the time of registration\r\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration\r\n* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for coagulation parameters are not required for entry into this protocol\r\n* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol\r\n* Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the treating physician may put the patient at high risk for radiation toxicity\r\n* Any other major medical illnesses or psychiatric impairments that in the investigator's opinion will prevent administration or completion of protocol therapy\r\n* Cognitive impairment that precludes a patient from acting as his or her own agent to provide informed consent
Subjects must not have a history of thromboembolic disorder or cerebral vascular disease
Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to day 1
Patients with clinically significant cardiovascular disease are excluded\r\n* Inadequately controlled hypertension (HTN) (systolic blood pressure [SBP] > 160 mmHg and/or diastolic blood pressure [DBP] > 90 mmHg despite antihypertensive medication)\r\n* History of cerebrovascular accident (CVA) within 6 months (see additional requirement for adjuvant protocols)\r\n* Myocardial infarction or unstable angina within 6 months (see additional requirement for adjuvant protocols)\r\n* New York Heart Association grade II or greater congestive heart failure \r\n* Serious and inadequately controlled cardiac arrhythmia\r\n* Significant vascular disease (e.g. aortic aneurysm, history of aortic dissection)\r\n* Clinically significant peripheral vascular disease
Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to day 1 of FOLFIRI + bevacizumab initiation
History of clinically significant vascular disease, including any of the following within 6 months prior to day 1 of study drug: myocardial infarction or unstable angina, percutaneous coronary intervention, bypass grafting, ventricular arrhythmia requiring medication, stroke or transient ischemic attack, symptomatic peripheral arterial disease and/or involvement of great vessels by tumor with or without vascular grafting
Severe peripheral vascular disease that would preclude catheterization
Severe peripheral vascular disease that would preclude catheterization
History of stroke, coronary arterial disease, angina, or vascular disease
Subjects with prosthetic cardiac valves, vascular grafts, pacers, or other non-removable vascular foreign body, with the exception of coronary stents and peripheral stents;
Has arterial vascular involvement
Clinical significant peripheral vascular disease or vascular disease (aortic aneurysm or aortic dissection)
Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, severe or unstable angina, myocardial infarction, symptomatic congestive heart failure (defined as New York Heart Association grade II or greater), arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks) or clinically significant ventricular arrhythmias within 6 months prior to randomization; or significant vascular disease (e.g., aortic aneurysm, aortic dissection), symptomatic peripheral vascular disease
Active collagen-vascular disease
Patient must not have had significant vascular disease (i.e. Moya-Moya, aortic aneurysm requiring surgical repair)
Significant vascular disease (e.g. aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to day 1
Patients who had, within the past 6 months, a cardiovascular accident (CVA) or at risk for arterial thrombus such as severe peripheral vascular disease (PVD) and carotid artery disease (CAD)
Clinically significant peripheral vascular disease
Patients must not have had significant vascular disease (eg, aortic aneurysm requiring surgical repair, deep venous or arterial thrombosis) within the last 6 months prior to study entry
Significant vascular disease (e.g., aortic aneurysm, aortic dissection)
Symptomatic peripheral vascular disease
Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to study enrolment.
Patients are excluded if they have known significant vascular disease (e.g., aortic aneurysm, aortic dissection)
Patients are excluded if they have symptomatic peripheral vascular disease
Patients with active vascular disease, either myocardial or peripheral (i.e. acute coronary syndrome, cerebral stroke, transient ischemic attack or arterial thrombosis or symptomatic peripheral vascular disease within the past 3 months);
Clinically significant peripheral vascular disease
Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to cycle 1, day 1
Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection) or clinically significant peripheral vascular disease
Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to day 1 of study drug
Patients with clinically significant peripheral vascular disease
Patients with significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to registration will not be eligible
Significant vascular disease (e.g., aortic aneurysm requiring surgical repair, or recent peripheral arterial thrombosis) within 6 months prior to Day 1 of treatment.
Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to day 1
Patients with clinically significant cardiovascular disease are excluded\r\n* Inadequately controlled hypertension (HTN) (systolic blood pressure [SBP] >= 160 mmHg and/or diastolic blood pressure [DBP] >= 90 mmHg despite antihypertensive medication)\r\n* History of cerebrovascular accident (CVA) within 6 months\r\n* Myocardial infarction or unstable angina within 6 months\r\n* New York Heart Association class II or greater congestive heart failure \r\n* Serious and inadequately controlled cardiac arrhythmia\r\n* Significant vascular disease (e.g. aortic aneurysm, history of aortic dissection)\r\n* Clinically significant peripheral vascular disease
Symptomatic peripheral vascular disease
Any other significant vascular disease (e.g., aortic aneurysm, aortic dissection, or carotid stenosis that requires medical or surgical intervention, including angioplasty or stenting)
Has any condition known to effect wound healing, such as collagen vascular disease
Participants should not have clinically significant peripheral vascular disease or vascular disease (including aortic aneurysm or aortic dissection)
No severe peripheral vascular disease
Symptomatic peripheral vascular disease
Significant vascular disease
Significant vascular disease
The patient has a known history of stroke, myocardial infarction, peripheral vascular disease, or recent (within 3 months) uncontrolled deep venous thrombosis.
Collagen vascular disease (lupus, scleroderma, rheumatoid arthritis)
Patients with symptomatic peripheral vascular disease are ineligible
Clinically significant peripheral vascular disease
Patients with symptomatic peripheral vascular disease are not eligible
Symptomatic arterial peripheral vascular disease
Clinically significant cardiovascular disease, such as:\r\n* Inadequately controlled hypertension (HTN) (for adults: systolic blood pressure [SBP] > 160 mmHg and/or diastolic blood pressure [DBP] > 90 mmHg despite antihypertensive medication; for children: please refer to \Grading and management of hypertension for adults and for children 6 through 17 years old\ for age-appropriate values indicating >= grade 2)\r\n* History of cerebrovascular accident (CVA) within 12 months\r\n* Myocardial infarction or unstable angina within 12 months\r\n* New York heart association grade II or greater congestive heart failure\r\n* Serious and inadequately controlled cardiac arrhythmia\r\n* Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection)\r\n* Clinically significant peripheral vascular disease
Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1.
No history of significant vascular disease (eg aortic aneurysm)
Significant vascular disease (e.g. aortic aneurysm surgical repair or recent peripheral arterial thrombosis) =< 6 months prior to randomization
Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to day 1
Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to day -3
Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to day 1
Clinically significant peripheral vascular disease
Significant vascular disease including aortic aneurysm, aortic dissection
Symptomatic peripheral vascular disease
Significant vascular (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to day 1
Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1
Subject has a grade II or greater peripheral vascular disease
Clinical significant peripheral vascular disease or vascular disease (aortic aneurysm or aortic dissection)
(continued from no. 13) CTCAE Grade 2 or greater peripheral vascular disease (at least brief (<24 hrs) episodes of ischemia managed non-surgically and without permanent deficit); Prior history of hypertensive crisis or hypertensive encephalopathy; Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1
Clinically significant peripheral vascular disease
Significant cardiac or peripheral vascular arterial disease
Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1
Subject has peripheral vascular disease
Clinically significant peripheral vascular disease
Cardiac or peripheral vascular disease meeting any of the following criteria:
Clinically-significant cardiac disease including:\r\n* Recent myocardial infarction (=< 6 months prior to first dose of mirvetuximab soravtansine)\r\n* Unstable angina pectoris\r\n* Uncontrolled congestive heart failure (New York Heart Association > class II)\r\n* Uncontrolled hypertension (>= Common Terminology Criteria for Adverse Events [CTCAE] version [v]4.03 grade 3), prior history of hypertensive crisis or hypertensive encephalopathy\r\n* Uncontrolled cardiac arrhythmias\r\n* Clinically-significant vascular disease (e.g. aortic aneurysm, or dissecting aneurysm)\r\n* Severe aortic stenosis\r\n* Clinically significant peripheral vascular disease\r\n* Cardiac toxicity >= grade 3 following prior chemotherapy\r\n* Corrected QT (QTc) > 470 for females and > 450 for males
Significant vascular disease or recent peripheral arterial thrombosis
History of significant vascular disease.
Clinical evidence of severe peripheral vascular disease, diabetic ulcers or venous stasis ulcers, or history of deep venous or arterial thrombosis within 3 months prior to screening
Significant vascular disease
Clinically significant cardiovascular disease defined as follows:\r\n* Inadequately controlled hypertension (i.e., systolic blood pressure [SBP] > 160 mm Hg and/or diastolic blood pressure [DBP] > 90 mm Hg despite antihypertensive therapy)\r\n* History of cerebrovascular accident (CVA) within 6 months\r\n* Myocardial infarction or unstable angina within 6 months\r\n* New York Heart Association classification II, III, or IV cardiovascular disease\r\n* Serious and inadequately controlled cardiac arrhythmia\r\n* Significant vascular disease (i.e., aortic aneurysm, history of aortic dissection)\r\n* Clinically significant peripheral vascular disease
History of significant vascular disease (i.e., aortic aneurysm requiring surgical repair, or recent peripheral arterial thrombosis) within 6 months prior to registration
Severe peripheral vascular disease in subjects whose Study Lesions are located in an extremity
Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection)
Significant vascular disease.
CTCAE grade 3 or greater peripheral vascular disease
Cerebral vascular accident
Severe, active co-morbidity, defined as follows:\r\n* Unstable angina and/or congestive heart failure within the last 6 months\r\n* Transmural myocardial infarction within the last 6 months\r\nNew York Heart Association grade II or greater congestive heart failure requiring hospitalization within 12 months prior to registration\r\n* History of stroke, cerebral vascular accident (CVA) or transient ischemic attack within 6 months\r\n* Serious and inadequately controlled cardiac arrhythmia\r\n* Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection) or clinically significant peripheral vascular disease\r\n* Evidence of bleeding diathesis or coagulopathy\r\n* Serious or non-healing wound, ulcer, or bone fracture or history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess, major surgical procedure or significant traumatic injury within 28 days prior to registration, with the exception of the craniotomy for tumor resection or follow-on craniotomies to manage complications of brain tumor management such as hemorrhage or infection\r\n* Bacterial or fungal infection requiring intravenous antibiotics at the time of registration\r\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration\r\n* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for coagulation parameters are not required for entry into this protocol\r\n Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the treating physician may put the patient at high risk for radiation toxicity \r\n* Any other major medical illnesses or psychiatric impairments that in the investigator's opinion will prevent administration or completion of protocol therapy\r\n* Cognitive impairment that precludes a patient from acting as his or her own agent to provide informed consent
No history of arterial thrombotic events within the past 6 months, including:\r\n* Transient ischemic attack (TIA)\r\n* Cerebrovascular accident (CVA)\r\n* Peripheral arterial thrombus\r\n* Unstable angina or angina requiring surgical or medial intervention\r\n* Myocardial infarction (MI)\r\n* Significant peripheral artery disease (i.e., claudication on less than one block)\r\n* Significant vascular disease (i.e., aortic aneurysm, history of aortic dissection)
Significant vascular disease (such as aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months of first study dose
Vascular disease resulting in clinically apparent compromise in blood flow to the treatment extremity (i.e. peripheral vascular disease with diminished pulses, venous insufficiency with clinical evidence of vascular congestion)
Active collagen vascular disease
Patients with collagen vascular disease are excluded
Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to day 1
Need for vascular resection/reconstruction
No symptomatic peripheral vascular obstructions
Collagen vascular disease such as lupus, or scleroderma
Previous diagnosis of collagen vascular disorder or vasculitis
The subject has a history of peripheral vascular disease
A history of cardiovascular disease, hypertension, or peripheral arterial/vascular disease;
A history of thromboembolic disorder or cerebral vascular disease
Subject has known lympho-vascular invasion
Significant vascular disease (such as aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 3 months of first study dose
Participants with known active collagen vascular disease
Measurable hepatic disease and/or presence of vascular tumor thrombosis
Participants with known active collagen vascular disease
Patient must not have had significant vascular disease (e.g., Moya-Moya, aortic aneurysm requiring surgical repair, deep venous or arterial thrombosis) =< 6 months prior to study entry
Have collagen vascular disease
NORMAL VOLUNTEERS: Have collagen vascular disease